AUA: Upper Tract Urothelial Carcinoma (2023): Difference between revisions

← Older edit Newer edit →

VisualWikitext

@@ Line 308: / Line 308: @@
 === Repeat endoscopic evaluation ===
-*Proclivity of UTUC to recur and for residual disease to remain after the first ablation
+*'''Should be performed within 3 months'''
-*'''Should be performed within three months'''
+**Proclivity of UTUC to recur and for residual disease to remain after the first ablation
 **A 30-day window on either side of this endpoint (i.e., 30 to 90 days) is justified to allow timely identification of recurrences and may be dictated by aspects such as tumor size, visualization, access, treatment efficacy, etc., as clinically indicated
-*'''Repeat endoscopic assessment should occur within three-month intervals until no evidence of upper tract disease is identified.'''
+*'''Repeat endoscopic assessment should occur within 3-month intervals until no evidence of upper tract disease is identified.'''
-*For patients with LR unfavorable disease who demonstrate progression in tumor size, focality, or grade, the Panel recommends against further endoscopic-assisted attempts and consideration of definitive resection via segmental ureterectomy (SU) or NU.
+* '''In patients with LR UTUC with evidence of risk group progression (tumor size, focality, or grade) or when tumor ablation is not feasible,''' further endoscopic-assisted attempts are not recommended. '''surgical resection of all involved sites either by RNU or segmental resection of the ureter should be offered.'''
-'''When tumor ablation is not feasible or evidence of risk group progression is identified in patients with LR UTUC, surgical resection of all involved sites either by RNU or segmental resection of the ureter should be offered.'''
+=== Surgical Resection ===
-=== Surgical management ===
 * '''RNU or SU is recommended for surgically eligible patients with HR UTUC'''